Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Treasury Shares: 2014-2025

Historic Treasury Shares for Arrowhead Pharmaceuticals (ARWR) over the last 12 years, with Sep 2025 value amounting to $2.7 million.

  • Arrowhead Pharmaceuticals' Treasury Shares was N/A to $2.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.7 million, marking a year-over-year change of. This contributed to the annual value of $2.7 million for FY2025, which is N/A change from last year.
  • Latest data reveals that Arrowhead Pharmaceuticals reported Treasury Shares of $53.2 million as of Q3 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Treasury Shares registered a high of $53.2 million during Q3 2025, and its lowest value of $53.2 million during Q3 2025.
  • Moreover, its 3-year median value for Treasury Shares was $4.8 million (2023), whereas its average is $4.7 million.
  • As far as peak fluctuations go, Arrowhead Pharmaceuticals' Treasury Shares fell by 3.21% in 2023, and later climbed by 18.91% in 2025.
  • Quarterly analysis of 5 years shows Arrowhead Pharmaceuticals' Treasury Shares stood at $3.6 million in 2021, then rose by 10.63% to $4.0 million in 2022, then climbed by 15.65% to $4.6 million in 2023, then climbed by 10.45% to $5.1 million in 2024, then rose by 18.91% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q3 2025, $6.0 million for Q2 2025, and $5.9 million during Q1 2025.